Monitoring Artemether-Lumefantrin (ALU) and Artesunate-Amodiaquin (AS-AQ) efficacy in uncomplicated malaria treatment in Bandiagara, and Doneguebougou

Monitoring Artemether-Lumefantrin (ALU) and Artesunate-Amodiaquin (AS-AQ) efficacy in uncomplicated malaria treatment in Bandiagara, and Doneguebougou¿s area, Mali.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201409000702188

Enrollment

320

Registered

2013-11-09

Start date

2012-10-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

Artemether-Lumefantrin or Artesunate-Amodiaquin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - age between 6 months-70 years; - résident in Bandiagara and area of Donéguébougou during study follow up periode ; - Be able to take tablet per os - Body temperature ¿ 37,5 degree Celsius or history of fievre within last 24 hours; - Plasmodium falciparum infection parasitemia between 2000 et 200 000 asexual forms/ul associated or not with P. ovale, P. malaria and/or P. vivax ; - consent of participant or/and parent (ou guardian) for children

Exclusion criteria

Exclusion criteria: Clinical signs of severe malaria or cerebral malaria according to WHO criteria - Patients with severe concomitant disease - Concomitant febrile disorders (otitis, Acute chest infection, tonsillitis and others) - Have a lower than 8 g / dl hemoglobin; - Known to be allergic to artemisinin derivatives; - Have a documented decision CTA in the last fifteen (15) days.

Design outcomes

Primary

Measure	Time frame
Time to parasite clearance, Proportion of subjects with Clinical and Parasitological Response Adequate, Proportion of subjects with parasitaemia on day 3	—

Secondary

Measure	Time frame
Time to gametocytes clearance;Time to fever clearance	—

Countries

Mali

Contacts

Public ContactDoumbo Ogobara K.

Prof in Parasitology-Mycology, Director of MRTC/DEAP

okd@icermali.org(223) 20 22 09 81

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026